China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA: 600062)
China
· Delayed Price · Currency is CNY 22.08
-0.16 (-0.72%)
Nov 21, 2024, 3:00 PM CST
China Resources Double-Crane Pharmaceutical Co.,Ltd. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 10,214 | 10,114 | 9,522 | 9,034 | 8,391 | 9,157 | Upgrade
|
| Other Revenue | 108.38 | 108.38 | 102.99 | 77.88 | 112.69 | 224.33 | Upgrade
|
| Revenue | 10,322 | 10,222 | 9,625 | 9,112 | 8,504 | 9,381 | Upgrade
|
| Revenue Growth (YoY) | -5.44% | 6.20% | 5.64% | 7.14% | -9.35% | 14.05% | Upgrade
|
| Cost of Revenue | 4,535 | 4,607 | 4,307 | 4,048 | 3,157 | 3,450 | Upgrade
|
| Gross Profit | 5,787 | 5,615 | 5,318 | 5,064 | 5,347 | 5,931 | Upgrade
|
| Selling, General & Admin | 3,680 | 3,470 | 3,478 | 3,502 | 3,764 | 4,354 | Upgrade
|
| Research & Development | 620.72 | 561.46 | 482.48 | 409.59 | 291.02 | 202.01 | Upgrade
|
| Other Operating Expenses | 78.42 | 98.3 | 119.35 | 115.75 | 114.41 | 136.87 | Upgrade
|
| Operating Expenses | 4,363 | 4,139 | 4,081 | 4,029 | 4,173 | 4,700 | Upgrade
|
| Operating Income | 1,424 | 1,477 | 1,237 | 1,034 | 1,173 | 1,231 | Upgrade
|
| Interest Expense | -11.8 | -14.07 | -10.62 | -11.62 | -3.66 | -9.5 | Upgrade
|
| Interest & Investment Income | 41.55 | 52.93 | 89.68 | 81.55 | 51.33 | 28.82 | Upgrade
|
| Earnings From Equity Investments | 66.26 | 12.55 | 16.23 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 6.32 | 6.32 | 18.06 | -4.97 | -0.48 | 0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 40.34 | 5.72 | 6.36 | 0.26 | -10.33 | -3.55 | Upgrade
|
| EBT Excluding Unusual Items | 1,567 | 1,540 | 1,357 | 1,099 | 1,210 | 1,247 | Upgrade
|
| Impairment of Goodwill | -28.9 | -28.9 | - | -56.68 | -43.42 | -24.54 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2.79 | 13.8 | 5.99 | 35.36 | 29.05 | 28.63 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.13 | -0.06 | -2.27 | 1.03 | -22.52 | -15.86 | Upgrade
|
| Asset Writedown | -89.14 | -50.63 | -8.43 | -0.54 | -0.12 | -27.58 | Upgrade
|
| Other Unusual Items | 92.35 | 92.35 | 82.76 | 42.65 | 41.92 | 54.48 | Upgrade
|
| Pretax Income | 1,543 | 1,567 | 1,435 | 1,121 | 1,215 | 1,262 | Upgrade
|
| Income Tax Expense | 189.53 | 240.61 | 201.27 | 149.06 | 201.52 | 195.34 | Upgrade
|
| Earnings From Continuing Operations | 1,354 | 1,326 | 1,234 | 972.13 | 1,013 | 1,066 | Upgrade
|
| Minority Interest in Earnings | -6.11 | 7.12 | -53.59 | -36.45 | -8.33 | -11.33 | Upgrade
|
| Net Income | 1,348 | 1,333 | 1,180 | 935.69 | 1,005 | 1,055 | Upgrade
|
| Net Income to Common | 1,348 | 1,333 | 1,180 | 935.69 | 1,005 | 1,055 | Upgrade
|
| Net Income Growth | -14.89% | 12.96% | 26.12% | -6.91% | -4.74% | 8.93% | Upgrade
|
| Shares Outstanding (Basic) | 1,027 | 1,025 | 1,036 | 1,043 | 1,043 | 1,043 | Upgrade
|
| Shares Outstanding (Diluted) | 1,027 | 1,025 | 1,036 | 1,043 | 1,043 | 1,043 | Upgrade
|
| Shares Change (YoY) | -0.71% | -0.99% | -0.74% | 0.00% | 0.00% | -0.01% | Upgrade
|
| EPS (Basic) | 1.31 | 1.30 | 1.14 | 0.90 | 0.96 | 1.01 | Upgrade
|
| EPS (Diluted) | 1.31 | 1.30 | 1.14 | 0.90 | 0.96 | 1.01 | Upgrade
|
| EPS Growth | -14.28% | 14.09% | 27.06% | -6.91% | -4.74% | 8.94% | Upgrade
|
| Free Cash Flow | 1,082 | 1,026 | 889.57 | 849.25 | 1,012 | 1,198 | Upgrade
|
| Free Cash Flow Per Share | 1.05 | 1.00 | 0.86 | 0.81 | 0.97 | 1.15 | Upgrade
|
| Dividend Per Share | 0.357 | 0.257 | 0.578 | 0.480 | 0.290 | 0.304 | Upgrade
|
| Dividend Growth | 23.53% | -55.54% | 20.42% | 65.52% | -4.61% | 8.96% | Upgrade
|
| Gross Margin | 56.06% | 54.93% | 55.25% | 55.57% | 62.87% | 63.22% | Upgrade
|
| Operating Margin | 13.79% | 14.44% | 12.85% | 11.35% | 13.80% | 13.12% | Upgrade
|
| Profit Margin | 13.06% | 13.04% | 12.26% | 10.27% | 11.82% | 11.25% | Upgrade
|
| Free Cash Flow Margin | 10.48% | 10.04% | 9.24% | 9.32% | 11.90% | 12.77% | Upgrade
|
| EBITDA | 2,095 | 2,092 | 1,778 | 1,482 | 1,548 | 1,591 | Upgrade
|
| EBITDA Margin | 20.30% | 20.46% | 18.47% | 16.26% | 18.20% | 16.96% | Upgrade
|
| D&A For EBITDA | 671.51 | 615.3 | 540.36 | 447.4 | 374.36 | 360.34 | Upgrade
|
| EBIT | 1,424 | 1,477 | 1,237 | 1,034 | 1,173 | 1,231 | Upgrade
|
| EBIT Margin | 13.79% | 14.44% | 12.85% | 11.35% | 13.80% | 13.12% | Upgrade
|
| Effective Tax Rate | 12.28% | 15.36% | 14.03% | 13.29% | 16.59% | 15.48% | Upgrade
|
| Revenue as Reported | 10,322 | 10,222 | 9,625 | 9,112 | 8,504 | 9,381 | Upgrade
|
| Advertising Expenses | - | - | - | - | 45.64 | 104.09 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.